Enteral formulation: low in fat and containing protein hydrolysates
US5998363A · kind A · utility
56Cited by
12References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 8, 1998 |
| Grant date | Dec 7, 1999 |
| Priority date | — |
| Expiry date | Oct 8, 2018 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA23V2002/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An improved enteral formulation that is low in fat and contains protein hydrolysates has been developed. The osmolality of the formulation is controlled to be below 500 mOs/kg H.sub.2 O, preferably about 300 mOs/kg H.sub.2 O. In a preferred embodiment, the formulation contains corn starch to control blood glucose levels. This formulation is particularly useful for treatment of critically ill patients and in minimizing a risk of pulmonary aspiration and/or gastrointestinal dysfunction in such patients.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.